Other
Mibc
3
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Mibc is an early-stage landscape with 3 programs across 4 companies. The most active players are Johnson & Johnson, Coherus Oncology, Inc., Pfizer. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Modality Breakdown
3programs
Small molecule133%
Monoclonal antibody133%
Antibody–drug conjugate133%
Modality classified for 100% of 3 pipeline programs.
Analysis
Trial Status
1
clinical trials
Recruiting1 · 100%
Clinical Trials
Trial Activity
Neoadjuvant RC48 Plus Gemcitabine for HER2 1~3+ MIBC: A Prospective, Multicenter, Randomized, Controlled, Non-inferiority Study (GUARD-02)
Recruiting·—·Phase 3·NCT07693959·170 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)